期刊
FRONTIERS IN CHEMISTRY
卷 7, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fchem.2019.00838
关键词
dementia; Alzheimer's disease; amyloid-beta peptide; Ru(III) complexes; peptide aggregation
资金
- Natural Sciences and Engineering Research Council (NSERC)
- Michael Smith Career Investigator Award
- Alzheimer's Association [NIRG-15-362537]
- Brain Canada
- NSERC USRA scholarship
- Science without borders (CAPES, Brazil) [0711/13-6]
Alzheimer's disease (AD) is the most common form of dementia, leading to loss of cognition, and eventually death. The disease is characterized by the formation of extracellular aggregates of the amyloid-beta (A beta) peptide and neurofibrillary tangles of tau protein inside cells, and oxidative stress. In this study, we investigate a series of Ru(III) complexes (Ru-N) derived from NAMI-A in which the imidazole ligand has been substituted for pyridine derivatives, as potential therapeutics for AD. The ability of the Ru-N series to bind to A beta was evaluated by NMR and ESI-MS, and their influence on the A beta peptide aggregation process was investigated via electrophoresis gel/western blot, TEM, turbidity, and Bradford assays. The complexes were shown to bind covalently to the A beta peptide, likely via a His residue. Upon binding, the complexes promote the formation of soluble high molecular weight aggregates, in comparison to peptide precipitation for peptide alone. In addition, TEM analysis supports both amorphous and fibrillar aggregate morphology for Ru-N treatments, while only large amorphous aggregates are observed for peptide alone. Overall, our results show that the Ru-N complexes modulate A beta peptide aggregation, however, the change in the size of the pyridine ligand does not substantially alter the A beta aggregation process.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据